Abstract:Qiu Huang, &ast Yue Ge, &ast Yu He, Jian Wu, Yonghua Tong, Haojie Shang, Xiao Liu, Xiaozhuo Ba, Ding Xia, Ejun Peng, Zhiqiang Chen, Kun Tang Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhiqiang Chen; Kun Tang, Email ; Cancer-associated fibroblasts (CAF) are the most abundant stromal cells in the tumor microenvironment (TME), especially in solid tumors. It has been confirmed that it can not only interact with tumor cells to promote cancer progression and metastasis, but also affect the infiltration and function of immune cells to induce chemotherapy and immunotherapy resistance. So, targeting CAF has been considered an important method in cancer treatment. The rapid development of nanotechnology provides a good perspective to improve the efficiency of targeting CAF. At present, more and more researches have focused on the application of nanoparticles (NPs) in targeting CAF. These studies explored the effects of different types of NPs on CAF and the multifunctional nanomedicines that can eliminate CAF are able to enhance the EPR effect which facilitate the anti-tumor effect of themselves. There also exist amounts of studies focusing on using NPs to inhibit the activation and function of CAF to improve the therapeutic efficacy. The application of NPs targeting CAF needs to be based on an understanding of CAF biology. Therefore, in this review, we first summarized the latest progress of CAF biology, then discussed the types of CAF-targeting NPs and the main strategies in the current. The aim is to elucidate the application of NPs in targeting CAF and provide new insights for engineering nanomedicine to enhance immune response in cancer treatment. Keywords: nanoparticles, cancer therapy, cancer-associated fibroblasts, drug delivery, cancer, nanomedicine In recent years, several barriers to effective tumor eradication, including the formation of distant metastasis, angiogenesis, drug resistance, and immunosuppression, have been identified. Consequently, there has been an increasing interest in the classification of different cells within the tumor parenchyma; these endeavors have led to the emergence of the tumor microenvironment (TME) concept. 1–6 Characterization of the TME has drawn attention to the deleterious role of cancer-associated fibroblasts (CAFs) in this context. 7 Under normal conditions, fibroblasts maintain a quiescent state and mainly contribute to the secretion of collagen, which supports the formation and integrity of the extracellular matrix (ECM), the fundamental tissue scaffold. 8,9 In the context of wound healing, fibroblasts become activated to facilitate tissue repair before undergoing apoptosis. 10 Tumors are often likened to "cancerous wounds" 11 that fail to heal and continuously stimulate fibroblasts through the secretion of cytokines such as TGF-β, 12 preventing them from returning to their resting state and promoting tumor growth. Recent investigations, however, have uncovered the presence of cancer-restraining CAF (rCAF) subtypes, which have tumor suppressor properties. 13 CAFs play significant roles in tumor proliferation, metastasis, chemotherapy resistance, cancer metabolism, immunotherapy resistance, and immune evasion, 14 which will be comprehensively discussed in this review. Consequently, CAF-targeting therapies have emerged; however, despite promising preclinical findings, the desired levels of efficacy have yet to be achieved and the clinical implementation of these therapies remains limited. 15 The past few decades have hailed rapid advancements in nanotechnology, which have facilitated the development and delivery of targeted drugs for cancer therapy. 16,17 However, results from clinical trials of anti-CAF drugs, such as vismodegib, navitoclax, and sibrotuzumab, have highlighted their uncontrollable toxicity and unstable action. 7,18 Drug encapsulation in nanoparticles (NPs) promises to overcome these challenges. NPs can optimize drug properties, reduce degradation rates in the body, improve solubility, enhance targeting capabilities, and improve overall drug efficacy. 19 Various types of NPs are available, including those constructed from lipids, metals, polymers, biological macromolecules, and cell membranes; each type has distinct properties and characteristics, which can be matched to a specific application. Moreover, coupling CAF-specific peptides or antibodies to the surface of NPs enables efficient targeting and drug release within these cells. 20,21 This review provides an overview of the characteristics of -Abstract Truncated-

Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers

Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers

Research Progress on Cancer-Associated Fibroblasts in Hepatocellular Carcinoma

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Nano-encapsulation of drugs to target hepatic stellate cells: Toward precision treatments of liver fibrosis

Nanoparticles Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Novel Nano-Based Drug Delivery Systems Targeting Hepatic Stellate Cells in the Fibrotic Liver

Nano-carriers for Delivery and Targeting of Active Ingredients of Chinese Medicine for Hepatocellular Carcinoma Therapy

Novel Dual CAFs and Cancer Cell Targeting Nano-Drug Delivery System for Anti-Fibrosis Mechanism of Liver Cancer

Hepatic Stellate Cell Membrane-Camouflaged Nanoparticles for Targeted Delivery of an Antifibrotic Agent to Hepatic Stellate Cells with Enhanced Antifibrosis Efficacy.

Cancer-associated Fibroblast-Targeted Nanodrugs Reshape Colorectal Tumor Microenvironments to Suppress Tumor Proliferation, Metastasis and Improve Drug Penetration

Development and Efficacy Evaluation of Nanoliposomes Targeting CAFs-LCSCs Communication for Hepatocellular Carcinoma Treatment

The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts

Nanotechnology-based combinational strategies toward the regulation of myofibroblasts and diseased microenvironment in liver fibrosis and hepatic carcinoma

Fibroblast Activation Protein-Α-adaptive Micelles Deliver Anti-Cancer Drugs and Reprogram Stroma Fibrosis

Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis

Targeting cancer-associated fibroblasts with hydroxyethyl starch nanomedicine boosts cancer therapy

Synergetic Regulation of Kupffer Cells, Extracellular Matrix and Hepatic Stellate Cells with Versatile CXCR4-inhibiting Nanocomplex for Magnified Therapy in Liver Fibrosis

Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles

A Tenascin C Targeted Nanoliposome with Navitoclax for Specifically Eradicating of Cancer-Associated Fibroblasts.